Alan Y Lu, Executive VP of RNAi developer Sirnaomics, talks to Scrip’s Brian Yang about the US-China hybrid's plan to develop anti-fibrosis therapies in both markets.
Small interfering RNA (siRNA) is a relatively new concept in China, where most innovative companies are betting on either small molecule or monoclonal antibodies for cancer treatment.
Headquartered in Gaithersburg, MD with subsidiaries in Suzhou and Guangzhou, China, Sirnaomics Inc. has filed an investigative new drug...
Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.
Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.
The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.
The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.
The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.
As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
